| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 31 | 2023 | 256 | 4.110 |
Why?
|
| Lupus Erythematosus, Systemic | 17 | 2017 | 986 | 1.620 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2023 | 654 | 1.540 |
Why?
|
| Genome-Wide Association Study | 9 | 2023 | 226 | 1.490 |
Why?
|
| Polymorphism, Single Nucleotide | 20 | 2022 | 537 | 1.080 |
Why?
|
| Genetic Loci | 4 | 2013 | 75 | 0.990 |
Why?
|
| Membrane Proteins | 2 | 2016 | 465 | 0.710 |
Why?
|
| Salivary Glands, Minor | 4 | 2021 | 21 | 0.590 |
Why?
|
| Carrier Proteins | 2 | 2016 | 245 | 0.580 |
Why?
|
| Interferon Regulatory Factors | 3 | 2016 | 57 | 0.540 |
Why?
|
| Immunity, Innate | 3 | 2013 | 205 | 0.540 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2016 | 3 | 0.540 |
Why?
|
| Autophagy-Related Proteins | 1 | 2016 | 9 | 0.530 |
Why?
|
| Adaptive Immunity | 2 | 2013 | 37 | 0.530 |
Why?
|
| Humans | 52 | 2023 | 26826 | 0.520 |
Why?
|
| Autoimmune Diseases | 4 | 2017 | 162 | 0.520 |
Why?
|
| African Americans | 8 | 2020 | 350 | 0.490 |
Why?
|
| Haplotypes | 9 | 2014 | 279 | 0.490 |
Why?
|
| B-Lymphocytes | 6 | 2020 | 275 | 0.470 |
Why?
|
| Antibodies, Antinuclear | 7 | 2023 | 181 | 0.450 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2015 | 276 | 0.430 |
Why?
|
| Nuclear Proteins | 5 | 2015 | 245 | 0.420 |
Why?
|
| Transcriptome | 3 | 2021 | 198 | 0.420 |
Why?
|
| Autoantibodies | 9 | 2023 | 466 | 0.410 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 439 | 0.410 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 9 | 0.400 |
Why?
|
| Egg Proteins | 1 | 2012 | 17 | 0.400 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2016 | 132 | 0.380 |
Why?
|
| Male | 30 | 2021 | 12869 | 0.370 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 19 | 0.370 |
Why?
|
| Female | 32 | 2021 | 14462 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 34 | 0.370 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 29 | 0.360 |
Why?
|
| DNA-Binding Proteins | 8 | 2016 | 481 | 0.360 |
Why?
|
| Salivary Glands | 3 | 2020 | 51 | 0.340 |
Why?
|
| Case-Control Studies | 8 | 2021 | 700 | 0.330 |
Why?
|
| Interferon Type I | 2 | 2020 | 55 | 0.310 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 7 | 2016 | 24 | 0.290 |
Why?
|
| Sarcoidosis | 3 | 2017 | 38 | 0.270 |
Why?
|
| Infertility, Male | 1 | 2006 | 23 | 0.270 |
Why?
|
| Spermatozoa | 1 | 2006 | 29 | 0.270 |
Why?
|
| Middle Aged | 16 | 2021 | 6817 | 0.240 |
Why?
|
| Germ-Line Mutation | 2 | 2015 | 29 | 0.240 |
Why?
|
| Cohort Studies | 7 | 2021 | 857 | 0.230 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 45 | 0.220 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1393 | 0.220 |
Why?
|
| Ribonucleoproteins | 5 | 2019 | 152 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 100 | 0.210 |
Why?
|
| Chromosomes, Human, X | 3 | 2017 | 35 | 0.210 |
Why?
|
| Lymphocytes | 3 | 2019 | 82 | 0.210 |
Why?
|
| Genotype | 4 | 2016 | 442 | 0.200 |
Why?
|
| Indians, North American | 2 | 2020 | 511 | 0.200 |
Why?
|
| Autoimmunity | 5 | 2021 | 153 | 0.200 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2021 | 13 | 0.190 |
Why?
|
| Alleles | 6 | 2021 | 345 | 0.190 |
Why?
|
| Interferons | 4 | 2019 | 68 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 93 | 0.180 |
Why?
|
| Antibody-Producing Cells | 2 | 2018 | 15 | 0.180 |
Why?
|
| Sex Chromosome Aberrations | 2 | 2017 | 16 | 0.180 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 76 | 0.180 |
Why?
|
| Neuromyelitis Optica | 1 | 2020 | 7 | 0.180 |
Why?
|
| Epithelium | 1 | 2020 | 39 | 0.170 |
Why?
|
| Th17 Cells | 1 | 2020 | 32 | 0.170 |
Why?
|
| Receptors, Fc | 1 | 2020 | 30 | 0.170 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 2 | 2017 | 11 | 0.170 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 45 | 0.170 |
Why?
|
| Lupus Nephritis | 2 | 2011 | 99 | 0.170 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 110 | 0.170 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2019 | 4 | 0.170 |
Why?
|
| Adult | 12 | 2020 | 7382 | 0.160 |
Why?
|
| Aged | 10 | 2020 | 5166 | 0.160 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 107 | 0.160 |
Why?
|
| HLA Antigens | 4 | 2023 | 57 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2021 | 240 | 0.160 |
Why?
|
| Genome, Human | 3 | 2023 | 67 | 0.160 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2018 | 15 | 0.150 |
Why?
|
| Autoantigens | 3 | 2019 | 212 | 0.150 |
Why?
|
| Mosaicism | 1 | 2017 | 12 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 445 | 0.150 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 9 | 0.140 |
Why?
|
| src-Family Kinases | 2 | 2016 | 71 | 0.140 |
Why?
|
| Cell Movement | 1 | 2019 | 353 | 0.140 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 53 | 0.140 |
Why?
|
| Biopsy | 4 | 2019 | 199 | 0.140 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 68 | 0.140 |
Why?
|
| Republic of Korea | 1 | 2016 | 9 | 0.130 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 14 | 0.130 |
Why?
|
| OX40 Ligand | 1 | 2016 | 16 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 10 | 0.130 |
Why?
|
| Klinefelter Syndrome | 1 | 2016 | 8 | 0.130 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 33 | 0.130 |
Why?
|
| Biomarkers | 4 | 2023 | 733 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2017 | 178 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 33 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 330 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 122 | 0.130 |
Why?
|
| Lymphoma | 1 | 2015 | 22 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 57 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 105 | 0.120 |
Why?
|
| RNA | 1 | 2015 | 104 | 0.120 |
Why?
|
| beta Karyopherins | 1 | 2014 | 13 | 0.120 |
Why?
|
| Antibody Specificity | 1 | 2014 | 113 | 0.120 |
Why?
|
| Exons | 1 | 2013 | 41 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 11 | 0.110 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2013 | 3 | 0.110 |
Why?
|
| HLA-DR3 Antigen | 1 | 2013 | 10 | 0.110 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 58 | 0.110 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2013 | 5 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 24 | 0.110 |
Why?
|
| Rheumatoid Factor | 3 | 2019 | 28 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 465 | 0.100 |
Why?
|
| Inflammation | 1 | 2017 | 601 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 453 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2013 | 229 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 400 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.100 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 12 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2011 | 21 | 0.100 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 130 | 0.100 |
Why?
|
| Phenotype | 2 | 2021 | 665 | 0.100 |
Why?
|
| Animals | 4 | 2021 | 9960 | 0.100 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2011 | 13 | 0.100 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 21 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 41 | 0.100 |
Why?
|
| Risk | 1 | 2011 | 133 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 36 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 623 | 0.090 |
Why?
|
| American Native Continental Ancestry Group | 1 | 2010 | 22 | 0.090 |
Why?
|
| Genomics | 1 | 2011 | 116 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 364 | 0.090 |
Why?
|
| Cell Line | 3 | 2023 | 672 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 945 | 0.090 |
Why?
|
| Mice | 3 | 2021 | 4406 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1475 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2021 | 1344 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 18 | 0.080 |
Why?
|
| Risk Factors | 3 | 2020 | 2010 | 0.070 |
Why?
|
| Trisomy | 2 | 2017 | 18 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2017 | 35 | 0.070 |
Why?
|
| Ethylnitrosourea | 1 | 2006 | 8 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2006 | 45 | 0.070 |
Why?
|
| DNA Repair | 1 | 2007 | 81 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 80 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 60 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2017 | 90 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2007 | 282 | 0.060 |
Why?
|
| Interleukins | 2 | 2017 | 108 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 397 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 910 | 0.060 |
Why?
|
| Prognosis | 2 | 2017 | 759 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2016 | 187 | 0.060 |
Why?
|
| CD4 Antigens | 1 | 2023 | 18 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2023 | 31 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 75 | 0.050 |
Why?
|
| Vimentin | 1 | 2023 | 26 | 0.050 |
Why?
|
| Florida | 1 | 2023 | 54 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2023 | 64 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 474 | 0.050 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2021 | 4 | 0.050 |
Why?
|
| ADAM17 Protein | 1 | 2021 | 13 | 0.050 |
Why?
|
| Thymocytes | 1 | 2021 | 12 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 49 | 0.050 |
Why?
|
| Fatigue | 1 | 2021 | 57 | 0.050 |
Why?
|
| Saliva | 1 | 2021 | 94 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2012 | 93 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 58 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 72 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 150 | 0.040 |
Why?
|
| Histological Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2019 | 63 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 273 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 189 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 782 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 177 | 0.040 |
Why?
|
| Glycosylation | 1 | 2018 | 69 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 3 | 0.040 |
Why?
|
| Turner Syndrome | 1 | 2017 | 7 | 0.040 |
Why?
|
| Apoptosis | 1 | 2021 | 739 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 94 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 139 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2017 | 44 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 12 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 204 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 115 | 0.040 |
Why?
|
| Linear Models | 1 | 2017 | 201 | 0.040 |
Why?
|
| United States | 2 | 2013 | 2032 | 0.040 |
Why?
|
| Oklahoma | 1 | 2020 | 973 | 0.030 |
Why?
|
| Receptors, CXCR5 | 1 | 2016 | 3 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2016 | 22 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 20 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 230 | 0.030 |
Why?
|
| Chromosomes, Human, Y | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 1927 | 0.030 |
Why?
|
| Hypergammaglobulinemia | 1 | 2016 | 7 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 2016 | 10 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 76 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 72 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 472 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 37 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 67 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2016 | 78 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 2 | 0.030 |
Why?
|
| France | 1 | 2015 | 15 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 182 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 9 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 18 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 69 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 70 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 716 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 278 | 0.030 |
Why?
|
| Lip | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 771 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 298 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 367 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 472 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 50 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 118 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 395 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 96 | 0.030 |
Why?
|
| Consensus | 1 | 2013 | 69 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2013 | 102 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 42 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 163 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Asian Americans | 1 | 2012 | 40 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 2012 | 12 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 253 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2012 | 27 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 324 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2012 | 46 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 32 | 0.030 |
Why?
|
| Pedigree | 1 | 2012 | 153 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 160 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 980 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 970 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1216 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 747 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 573 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 59 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1036 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2007 | 2 | 0.020 |
Why?
|
| Alkalies | 1 | 2007 | 6 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 36 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2007 | 24 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 40 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 261 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2007 | 155 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2581 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 2957 | 0.020 |
Why?
|
| DNA | 1 | 2007 | 365 | 0.020 |
Why?
|